ClinicalTrials.gg
Not yet recruitingNCT07435103ASD; XeUpdated Feb 27, 2026

Xenon Therapy for Children With Autism Spectrum Disorder

A Phase 1/2 interventional study of Xenon in Autism Spectrum Disorder (ASD) and Autism, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Autistic Disorder with a site in China — 13 open to participants now, 15 under way, none of them phase 3. Autistic Disorder · China.

Planned enrollment
10th of 20
72 · median 66
Started
2026
with 1 other
Phase 1/2
2 of 26
1 open now
Primary completion
2027-03
later than 8 of 14 live
Registered
21st of 26
by date

Among the 26 studies in Autistic Disorder with a site in China, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 8 of the 14 other live ones, and was the 21st registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

13 of the 26 studies in Autistic Disorder with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Autistic Disorder with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of inhaled xenon for the treatment of children with autism spectrum disorder (ASD). The primary objective is to determine whether short-term inhalational xenon therapy can improve social functioning in children with ASD, as measured by changes in the Social Responsiveness Scale (SRS). Safety and tolerability of xenon inhalation in the pediatric population will also be assessed.

In this randomized, placebo-controlled trial, participants will receive either inhaled xenon or a placebo gas (medical air without xenon) to compare treatment effects.

Participants will:

Inhale 25% xenon or placebo for 10 minutes per day for 10 consecutive days Attend two clinical visits: one immediately after completion of the intervention and one at 3 months post-intervention for follow-up assessments and safety evaluations

03

Conditions studied

  • Autism Spectrum Disorder (ASD)
  • Autism

Browse trials for

04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's planned enrollment of 72 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

The Children's Hospital of Zhejiang University School of Medicine is the lead sponsor of 69 studies on the registry; 52 are open to participants now.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 4-18 years, with no gender restriction.
  • Meeting the diagnostic criteria for Autism Spectrum Disorder (ASD) as specified in the (5th Edition) (DSM-5), with the diagnosis confirmed by assessment using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2).
  • The total T-score on the Social Responsiveness Scale, Second Edition (SRS-2) is ≥90.
  • No treatment such as neuromodulation (transcranial magnetic stimulation, transcranial electrical stimulation) has been received for at least 1 month prior to randomization.
  • For participants who have previously taken psychotropic medications prior to randomization, it is required that the medications have been discontinued for a minimum of 5 half-lives or 4 weeks, whichever is longer.
  • The participants and their legal guardians confirm that they will not add new or alter the existing established treatment regimens such as behavioral rehabilitation during the study period.
  • The legal guardians of the participants have a full understanding of the study content, participate voluntarily, and sign a written form.

Exclusion criteria

Exclusion Criteria:

  • Having other major neurological diseases (e.g., epilepsy, cerebral palsy), severe physical illnesses, or genetic syndromes.
  • Having severe auditory or visual impairments that prevent the completion of assessments with cooperation.
  • A history of anaphylaxis or adverse reactions to Xenon.
  • Currently participating in or having participated in other interventional clinical trials within the recent 3 months.
  • The investigator judges that there is any condition that may increase the risk to the participant or interfere with the conduct of the trial and the assessment of its results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (estimated)

Study arms

  • Placebo comparator
    Participants inhaled 30% oxygen, 10 min/day, for 10 days

    Children aged 4-8 years with autism spectrum disorder in the control group underwent a daily 10-minute inhalation of 30% oxygen (delivered via face mask at 2 L/min) for 10 consecutive days.

    Drug: Xenon

  • Experimental
    Participants inhaled a mixture of 25% Xenon, 10 min/day, for 10 days

    Children aged 4-8 years with autism spectrum disorder in the treatment group underwent a daily 10-minute inhalation of 25% Xenon (delivered via face mask at 2 L/min) for 10 consecutive days.

    Drug: Xenon

Interventions

  • DrugXenon

    Children aged 4-18 with autism spectrum disorder inhaled a mixture of 25% Xenon via a face mask at an oxygen flow rate of 2 L/min, for 10 minutes per day for 10 day.

    Also known as: Xe

07

What researchers measure

Primary outcomes

  1. Core symptom outcomes

    For the assessment of core symptom outcomes, the social responsiveness scale, Second Edition was used.Raw scores were converted to age- and sex-normed T-scores, with a minimum obtainable T-score of 30. A total T-score of 60 or higher indicates clinically significant symptom severity, whereas T-scores of 59 or below are considered within the normal range.

    Time frame: From enrollment to the end of treatment at 3 months.

Secondary outcomes

  1. Core symptom outcomes

    For the assessment of core symptom outcomes, the Autism Diagnostic Observation Schedule (ADOS-2) was used.

    Time frame: From enrollment to the end of treatment at 3 months.

  2. Aberrant behavior outcomes

    For the assessment of aberrant behavior outcomes, the Aberrant behavior Checklist (ABC) scale was used.

    Time frame: From enrollment to the end of treatment at 3 months.

  3. Treatment efficacy

    For the assessment of treatment efficacy, the Autism Treatment Evaluation Checklist scale was used. The Autism Treatment Evaluation Checklist total score ranges from a minimum of 0 (no autism symptoms) to a maximum of 179 (severe impairment), with lower scores indicating fewer symptoms and higher scores indicating greater severity.

    Time frame: From enrollment to the end of treatment at 3 months.

  4. Severity

    For the assessment of behavioral severity, the Clinical Impressions Severity of illness (CGI-S) was used.

    Time frame: From enrollment to the end of treatment at 3 months.

  5. Improvements

    For the assessment of behavioral improvements after treatment, the Clinical Global Impressions scale for Improvement (CGI-I) scale was used.The Clinical Global Impressions-Improvement scale is a 7-point scale ranging from 1 ("Very much improved") to 7 ("Very much worse"), with a score of 4 indicating "No change."

    Time frame: From enrollment to the end of treatment at 3 months.

  6. Sleep problems

    For the assessment of sleep problems, the Children's Sleep Habits Questionnair (CSHQ) was used.

    Time frame: From enrollment to the end of treatment at 3 months.

  7. Brain functions

    For the assessment of brian functions, the MRI imaging was used.

    Time frame: From enrollment to the end of treatment at 3 months.

08

Study locations

1 site
  • Children's Hospital Affiliated to Zhejiang University School of Medicine (Binjiang Campus)
    Hangzhou, Zhejiang 310000, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 27, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07435103
Lead sponsor
The Children's Hospital of Zhejiang University School of Medicine
Responsible party
Daqing Ma (Professor, The Children's Hospital of Zhejiang University School of Medicine) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Jin piao Zhu, Associate fellow
Contact
zhujinpiao@zju.edu.cn
0571-81732399

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xenon

Start the discussion